20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Update

20/20 Biolabs Inc (NASDAQ:AIDX) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 46,806 shares, a decrease of 50.4% from the August 31st total of 94,280 shares. Based on an average daily volume of 58,991 shares, the short-interest ratio is presently 0.8 days. Approximately 0.5% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.00.

20/20 Biolabs Stock Up 6.6%

AIDX stock traded up $0.03 during trading hours on Tuesday, hitting $0.44. The company’s stock had a trading volume of 8,899 shares, compared to its average volume of 438,580. The stock has a 50 day moving average price of $0.51 and a two-hundred day moving average price of $1.00. 20/20 Biolabs has a 12 month low of $0.40 and a 12 month high of $50.00. The company has a market capitalization of $5.57 million and a PE ratio of -0.81.

20/20 Biolabs (NASDAQ:AIDX) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. The company had revenue of $0.73 million for the quarter.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.